Adair K. Minihan

Adair K. Minihan

Auto-generated profile, based on publicly available information

Adair K. Minihan

Surveillance & Health Equity Science, American Cancer Society , Atlanta, GA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JSJessica Star
Jessica Star
PBPriti Bandi
Priti Bandi
RSRebecca L. Siegel
Rebecca L. Siegel
XHXuesong Han
Xuesong Han
AMAdair Minihan
Adair Minihan
AJAhmedin Jemal
Ahmedin Jemal
PURPOSE: To examine whether cancer screening prevalence in the United States during 2021 has returned to prepandemic levels using nationally representative data. METHODS: Information on receipt of age-eligible screening for breast (women age 50-74 years), cervical (women without a hysterectomy age 21-65 years), prostate (men age 55-69 years), and colorectal cancer (men and women age 50-75 years) according to the US Preventive Services Task Force recommendations was obtained from the 2019 and 2021 National Health Interview Survey. Past-year screening prevalence in 2019 and 2021 and adjusted prevalence ratios (aPRs), 2021 versus 2019, with their 95% CIs were calculated using complex survey logistic regression models. RESULTS: Between 2019 and 2021, past-year screening in the United States decreased from 59.9% to 57.1% (aPR, 0.94; 95% CI, 0.91 to 0.97) for breast cancer, from 45.3% to 39.0% (aPR, 0.85; 95% CI, 0.82 to 0.89) for cervical cancer, and from 39.5% to 36.3% (aPR, 0.9; 95% CI, 0.84 to 0.97) for prostate cancer. Declines were most notable for non-Hispanic Asian persons. Colorectal cancer screening prevalence remained unchanged because an increase in past-year stool testing (from 7.0% to 10.3%; aPR, 1.44; 95% CI, 1.31 to 1.58) offset a decline in colonoscopy (from 15.5% to 13.8%; aPR, 0.88; 95% CI, 0.83 to 0.95). The increase in stool testing was most pronounced in non-Hispanic Black and Hispanic populations and in persons with low socioeconomic status. CONCLUSION: Past-year screening prevalence for breast, cervical, and prostate cancer among age-eligible adults in the United States continued to be lower than prepandemic levels in the second year of the COVID-19 pandemic, reinforcing the importance of return to screening health system outreach and media campaigns. The large increase in stool testing emphasizes the role of home-based screening during health care system disruptions. [Media: see text]

18 April 2023 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
PBPriti Bandi
Priti Bandi
JSJessica Star
Jessica Star
AMAdair K. Minihan
Adair K. Minihan
MPMinal Patel
Minal Patel
NNNigar Nargis
Nigar Nargis
AJAhmedin Jemal
Ahmedin Jemal

4 January 2024 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
JSJessica Star
Jessica Star
RSRebecca L Siegel
Rebecca L Siegel
AMAdair K Minihan
Adair K Minihan
RSRobert A Smith
Robert A Smith
AJAhmedin Jemal
Ahmedin Jemal
PBPriti Bandi
Priti Bandi
Several organizations now recommend that individuals at average risk for colorectal cancer (CRC) begin screening at 45 rather than 50 years of age. We present contemporary estimates of CRC screening in newly eligible adults aged 45 to 49 years between 2019 and 2021. Nationally representative prevalence estimates and population number screened were estimated based on the National Health Interview Survey. A logistic regression model assessed CRC screening prevalence differences by survey year and sociodemographic characteristics. In 2021, 19.7%—that is, fewer than 4 million of the eligible 19 million adults aged 45 to 49 years—were up-to-date on CRC screening. Screening was lowest in those who were uninsured (7.6%), had less than a high school diploma (15.4%), and Asian (13.1%). Additionally, fecal occult blood test and/or fecal immunochemical testing was underused, with only 2.4% (<460 000 people) reporting being up-to-date with screening using this modality in 2021. CRC screening in eligible young adults remains low. Concerted efforts to improve screening are warranted, particularly in underserved populations.

26 April 2023 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
JSJessica Star
Jessica Star
PBPriti Bandi
Priti Bandi
NNNigar Nargis
Nigar Nargis
FIFarhad Islami
Farhad Islami
KYK. Robin Yabroff
K. Robin Yabroff
AJAhmedin Jemal
Ahmedin Jemal
We present national and state representative prevalence estimates of modifiable cancer risk factors, preventive behaviors and services, and screening, with a focus on changes during the COVID-19 pandemic. Between 2019 and 2021, current smoking, physical inactivity, and heavy alcohol consumption declined, and human papillomavirus vaccination and stool testing for colorectal cancer screening uptake increased. In contrast, obesity prevalence increased, while fruit consumption and cervical cancer screening declined during the same timeframe. Favorable and unfavorable trends were evident during the second year of the COVID-19 pandemic that must be monitored as more years of consistent data are collected. Yet disparities by racial/ethnic and socioeconomic status persisted, highlighting the continued need for interventions to address suboptimal levels among these population subgroups.

21 October 2022 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
JSJessica Star
Jessica Star
XHXuesong Han
Xuesong Han
LMLaura A. Makaroff
Laura A. Makaroff
AMAdair K. Minihan
Adair K. Minihan
AJAhmedin Jemal
Ahmedin Jemal
PBPriti Bandi
Priti Bandi

24 October 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
RZRan Zhao
Ran Zhao
SKShalini Kulasingam
Shalini Kulasingam
FAFernando Alarid-Escudero
Fernando Alarid-Escudero
AMAdair K Minihan
Adair K Minihan
MNMadalyn Nones
Madalyn Nones
AJAhmedin Jemal
Ahmedin Jemal
Background: Cervical cancer poses a substantial burden in the United States. State-level decision makers need to understand the expected benefits of implementing interventions to reduce this burden. This study aimed to estimate the long-term state-level benefits of interventions to reduce the burden of cervical cancer. Methods: We used a simulation model to estimate the expected reductions in cervical cancer incidence and mortality by achieving 80% (or 90%) vaccination coverage among adolescents aged 13-17 years by 2030 and increasing screening uptake by 5% among women aged 21-65 years across all 50 US states who had never been screened. We modeled 1 status quo scenario and 3 intervention scenarios: increasing vaccination only, increasing screening only, and increasing both vaccination and screening. The benefits of each intervention were presented as the cumulative reduction in cancer incidence and mortality compared with the status quo over a 100-year analytic period. Results: Compared with the status quo, the cumulative reduction from the “increase in vaccination coverage only” scenario varied substantially by state, generally being higher in Southern and Western states. The greatest reductions were predicted for Mississippi, with 253.1 cases and 80.0 deaths per 100 000 women. The “increase in both vaccination and screening” scenario reduced cancer incidence from 9.2 (Utah) to 266.0 (Mississippi) per 100 000 women and reduced mortality from 3.3 (Utah) to 85.0 (Mississippi) per 100 000 women. Conclusion: Our modeling study suggests that states and regions will differ in the extent to which they will benefit from increasing human papillomavirus vaccination coverage and cervical cancer screening uptake.